These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 2419882)

  • 1. Development of a model for the induction of estrogen-related prostatic hyperplasia in the dog and its response to the aromatase inhibitor 4-hydroxy-4-androstene-3,17-dione: preliminary results.
    Habenicht UF; Schwarz K; Schweikert HU; Neumann F; el Etreby MF
    Prostate; 1986; 8(2):181-94. PubMed ID: 2419882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergic inhibitory effects of the aromatase inhibitor 1-methyl-androsta-1, 4-diene-3, 17-dione and the antiandrogen cyproterone acetate on androstenedione-induced hyperplastic effects in the prostates of castrated dogs.
    Habenicht UF; el Etreby MF
    Prostate; 1987; 11(2):133-43. PubMed ID: 2444953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atamestane: an aromatase inhibitor for the treatment of benign prostatic hyperplasia. A short review.
    el Etreby MF
    J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):565-72. PubMed ID: 7682838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a new steroidal aromatase inhibitor, TZA-2237, and/or chlormadinone acetate on hormone-induced and spontaneous canine benign prostatic hyperplasia.
    Ito K; Fukabori Y; Shibata Y; Suzuki K; Mieda M; Gotanda K; Honma S; Yamanaka H
    Eur J Endocrinol; 2000 Oct; 143(4):543-54. PubMed ID: 11022202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale for using aromatase inhibitors to manage benign prostatic hyperplasia. Experimental studies.
    Habenicht UF; el Etreby MF
    J Androl; 1991; 12(6):395-402. PubMed ID: 1722796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of estrogen-related hyperplastic changes in the prostate of the cynomolgus monkey (Macaca fascicularis) by androstenedione and its antagonization by the aromatase inhibitor 1-methyl-androsta-1,4-diene-3,17-dione.
    Habenicht UF; Schwarz K; Neumann F; el Etreby MF
    Prostate; 1987; 11(4):313-26. PubMed ID: 2446299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective inhibition of androstenedione-induced prostate growth in intact beagle dogs by a combined treatment with the antiandrogen cyproterone acetate and the aromatase inhibitor 1-methyl-androsta-1,4-diene-3,17-dione (1-methyl-ADD).
    Habenicht UF; el Etreby MF
    Prostate; 1989; 14(4):309-22. PubMed ID: 2473459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of aromatase inhibitor, TZA-2209, on the prostate of androstenedione-treated castrated dogs: changes in prostate volume and histopathological findings.
    Suzuki K; Ito K; Tamura Y; Suzuki T; Honma S; Yamanaka H
    Prostate; 1996 May; 28(5):328-37. PubMed ID: 8610061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of estrogen deprivation on human benign prostatic hyperplasia.
    Schweikert HU; Tunn UW; Habenicht UF; Arnold J; Senge T; Schulze H; Schröder FH; Blom JH; Ennemoser O; Horniger W
    J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):573-6. PubMed ID: 7682839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of benign prostatic hyperplasia with particular emphasis on aromatase inhibitors.
    Habenicht UF; Tunn UW; Senge T; Schröder FH; Schweikert HU; Bartsch G; el Etreby MF
    J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):557-63. PubMed ID: 7682837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of metachromasia in experimentally induced hyperplastic/hypertrophic changes in the prostate of the cynomolgus monkey (Macaca fascicularis).
    Habenicht UF; el Etreby MF; Lewis R; Ghoniem G; Roberts J
    J Urol; 1989 Dec; 142(6):1624-6. PubMed ID: 2479780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atamestane, a new aromatase inhibitor for the management of benign prostatic hyperplasia.
    el Etreby MF; Nishino Y; Habenicht UF; Henderson D
    J Androl; 1991; 12(6):403-14. PubMed ID: 1722797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The function and the role of aromatase inhibitors in the treatment of BPH.
    el Etreby MF; Habenicht UF
    Prog Clin Biol Res; 1994; 386():209-30. PubMed ID: 7528389
    [No Abstract]   [Full Text] [Related]  

  • 14. Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group.
    Radlmaier A; Eickenberg HU; Fletcher MS; Fourcade RO; Reis Santos JM; van Aubel OG; Bono AV
    Prostate; 1996 Oct; 29(4):199-208. PubMed ID: 8876703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism of androgens in human benign prostatic hyperplasia: aromatase and its inhibition.
    Bartsch W; Klein H; Stürenburg HJ; Voigt KD
    J Steroid Biochem; 1987; 27(1-3):557-64. PubMed ID: 2447391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aromatase inhibitors and benign prostatic hyperplasia.
    Henderson D; Habenicht UF; Nishino Y; Kerb U; el Etreby MF
    J Steroid Biochem; 1986 Nov; 25(5B):867-76. PubMed ID: 2433507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of long-term administration of androgens and estrogen on rhesus monkey prostate: possible induction of benign prostatic hyperplasia.
    Jeyaraj DA; Udayakumar TS; Rajalakshmi M; Pal PC; Sharma RS
    J Androl; 2000; 21(6):833-41. PubMed ID: 11105909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bakuchiol suppresses oestrogen/testosterone-induced Benign Prostatic Hyperplasia development through up-regulation of epithelial estrogen receptor β and down-regulation of stromal aromatase.
    Miao L; Jiao C; Shao R; Qi Y; Fan G; Li X; Wang Y; Zhu Y; Zhang J; Gao X
    Toxicol Appl Pharmacol; 2019 Oct; 381():114637. PubMed ID: 31238046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Placebo controlled double-blind study to test the efficacy of the aromatase inhibitor atamestane in patients with benign prostatic hyperplasia not requiring operation. The Schering 90.062 Study Group.
    Gingell JC; Knönagel H; Kurth KH; Tunn UW
    J Urol; 1995 Aug; 154(2 Pt 1):399-401. PubMed ID: 7541854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aromatase inhibitors: their biochemistry and clinical potential.
    Henderson D
    J Steroid Biochem; 1987; 27(4-6):905-14. PubMed ID: 2447395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.